Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.42 |
| ▸ | HTR2B | P41595 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787733 | 0.87 | HTR2C (0.42) | HTR2CLMNATSHRPARP1 | |
| SCHEMBL6787727 | 0.87 | HTR2C (0.42) | HTR2CLMNATSHRPARP1 | |
| SCHEMBL1226267 | 0.86 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL292288 | 0.86 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL1226270 | 0.86 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL1226161 | 0.86 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL1226165 | 0.86 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL1173166 | 0.83 | HTR2A (0.59) | HTR2CHTR2AHTR2BCHRNB4CHRNA3 | |
| SCHEMBL1173167 | 0.83 | HTR2A (0.59) | HTR2CHTR2AHTR2BCHRNB4CHRNA3 | |
| SCHEMBL13633921 | 0.83 | HTR2A (0.59) | HTR2CHTR2AHTR2BCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | claimed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | claimed |
| EP-3182971-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX Cardio, LLC (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016029037-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2016-02-25 | — | — | WO | claimed |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | claimed |
| US-7612063-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | claimed |
| EP-1874731-A4 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20080261963-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | claimed |
| US-7381720-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | claimed |
| US-20060229303-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2006-10-12 | — | — | US | claimed |
| WO-2006078317-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-20060063761-A1 | Novel benzothiazole compounds and methods of use thereof | SENHWA BIOSCIENCES, INC. (TW) | 2006-03-23 | — | — | US | claimed |
| WO-2006015150-A1 | CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF | CYLENE PHARMACEUTICALS (US) | 2006-02-09 | — | — | WO | claimed |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | CYLENE PHARMACEUTICALS | 2006-02-02 | — | — | US | claimed |
| EP-1610759-A2 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | Cylene Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | claimed |
| EP-1610795-A2 | HETEROCYCLIC SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE ANALOGS | Cylene Pharmaceuticals, Inc. (US) | 2006-01-04 | — | — | EP | claimed |
| US-20050004160-A1 | Heterocyclic substituted 1,4-dihydri-4-0x9-1,8-naphthyridine analogs | CYLENE PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004091627-A2 | HETEROCYCLIC SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| WO-2004091504-A2 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | HTR2C 3890/4885HTR2A 3889/4885HTR2B 3789/4885 |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | PIN1, HPD, DHPS | HTR2C 3458/4885HTR2A 3722/4885HTR2B 3533/4885 |
| US-20060229303-A1 | Substituted quinobenzoxazine analogs | CYP3A5, UGT2B7, CYP2D6 | HTR2C 1074/4885HTR2A 832/4885HTR2B 760/4885 |
| US-20060063761-A1 | Novel benzothiazole compounds and methods of use thereof | MLNR, CCKBR, CYP2B6 | HTR2C 430/4885HTR2A 843/4885HTR2B 468/4885 |
| US-20080261963-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | HTR2C 1074/4885HTR2A 832/4885HTR2B 760/4885 |
| US-20050004160-A1 | Heterocyclic substituted 1,4-dihydri-4-0x9-1,8-naphthyridine analogs | CYP2C9, CYP4X1, UGT1A9 | HTR2C 1411/4885HTR2A 1637/4885HTR2B 1119/4885 |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | HTR2C 1074/4885HTR2A 832/4885HTR2B 760/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | HTR2C 3890/4885HTR2A 3889/4885HTR2B 3789/4885 |
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYP2W1, NQO2, UGT2B7 | HTR2C 1023/4885HTR2A 853/4885HTR2B 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.